Project Grant R41AG044871

This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $372,400 to Nova Southeastern University to conduct research comparing the therapeutic potential of three compounds - tirzepatide, retatrutide, and crocetin - in mitigating Alzheimer's-like pathology in a mouse model of comorbid Alzheimer's disease and obesity/prediabetes. The 3-year study, running from December 2024 to November 2027, will assess the impact of these interventions on...

This federal Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $499,441 to Acepre, LLC to develop a novel brain-targeted delivery system for the compound N-acetylcysteine (TN-NAC) as a potential treatment for Alzheimer's disease (AD). The key objectives of this Phase I STTR study are to: 1) evaluate the toxicity and pharmacokinetic properties of TN-NAC in mice, and 2) test the therapeutic efficacy of TN-NAC in a 3xTG-AD mouse model of...

Federal Project Grant Award Summary Artery Therapeutics, Inc. received a $2.45 million Project Grant from the National Institute on Aging under the Aging Research program (CFDA 93.866) awarded September 10, 2025, with completion targeted for August 31, 2026. The primary deliverable is the manufacturing of approximately 2.3 kilograms of Good Manufacturing Practice (GMP)-compliant CS6253, an ATP-binding cassette transporter A1 (ABCA1) agonist small molecule peptide, to support chronic toxicology...

The National Institutes of Health National Institute on Aging awarded Arviat Pharmaceuticals, Inc. a $1,350,180 Project Grant under the Aging Research program (CFDA 93.866) on September 30, 2021 to develop novel small-molecule inhibitors of the 12/15-lipoxygenase enzyme family. The goal is to reduce neuroinflammation and slow disease progression in Alzheimer's disease by inhibiting 12/15-LO activity. Under the award, Arviat will screen compounds from existing patent portfolios and develop...

Novelmed Therapeutics, Inc. was awarded a $900,000 Project Grant from the National Institutes of Health's National Institute on Aging to develop a selective inhibitor of the alternative pathway of complement as a treatment for Neuromyelitis Optica Spectrum Disorder. Under the grant, Novelmed will conduct preclinical studies to evaluate its lead drug candidate NM5072, including in vitro and ex vivo assays to confirm the drug's mechanism of action and selective inhibition of the alternative...

This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $426,250 to Wake Forest University Health Sciences to develop and evaluate a novel positron emission tomography (PET) radiotracer, [11C]TM-N1324, to measure levels of the G-protein coupled receptor GPR39 in rodent models and postmortem human brain tissues of Alzheimer's disease (AD). The project aims to establish the utility of this PET imaging approach for quantifying GPR39, which is implicated...

The National Institute on Aging (NIA) awarded a $1,161,852 project grant under the Aging Research (CFDA 93.866) program to Wayne State University (WSU) to investigate the neuroprotective properties of the drug canagliflozin and its potential to improve cognitive function during aging. The project will assess canagliflozin's effects on neuroinflammation, insulin responsiveness, and cognitive performance in aged mice, including mouse models of Alzheimer's disease. WSU is collaborating with The...

Federal Project Grant Award Summary The National Institute on Aging (NIA) awarded Advantage Therapeutics, Inc. a Project Grant of $1,249,957 (awarded September 20, 2025) under the Aging Research program (CFDA 93.866) to conduct preclinical and Investigational New Drug (IND)-enabling studies on a novel small-molecule disease-modifying therapeutic for Alzheimer's disease. The proposed treatment is designed to reduce brain inflammation and restore phagocytosis, thereby improving amyloid...

Federal Cooperative Agreement Award Summary Award Overview Artery Therapeutics, Inc. received a $2.64 million Cooperative Agreement from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), awarded February 15, 2026, with an ultimate completion date of March 15, 2028. The awardee will conduct clinical research and development services for CS6253, an ABCA1 (ATP-binding-cassette-transporter A1) agonist therapeutic candidate targeting hereditary APOE4...

This Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $2,181,250 in funding to the Seattle Institute For Biomedical And Clinical Research to develop small molecule inhibitors of the MSUT2 protein as a potential therapeutic approach for treating tauopathy disorders such as frontotemporal lobar degeneration, Alzheimer's disease, and related conditions. The project aims to optimize potent and brain-penetrant MSUT2 inhibitors and demonstrate...